Compare TBLA & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TBLA | NBTX |
|---|---|---|
| Founded | 2007 | 2003 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | N/A | 2020 |
| Metric | TBLA | NBTX |
|---|---|---|
| Price | $4.63 | $22.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | $4.80 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 1.7M | 30.9K |
| Earning Date | 11-05-2025 | 09-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $1,880,771,000.00 | $11,930,711.00 |
| Revenue This Year | $11.25 | N/A |
| Revenue Next Year | $5.55 | $145.24 |
| P/E Ratio | $58.27 | ★ N/A |
| Revenue Growth | ★ 10.96 | N/A |
| 52 Week Low | $2.50 | $2.82 |
| 52 Week High | $4.64 | $30.35 |
| Indicator | TBLA | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 74.89 | 56.96 |
| Support Level | $3.93 | $21.67 |
| Resistance Level | $4.22 | $23.68 |
| Average True Range (ATR) | 0.13 | 0.90 |
| MACD | 0.05 | -0.02 |
| Stochastic Oscillator | 97.42 | 69.46 |
Taboola.com Ltd is a technology company that powers recommendations across the Open Web with an artificial intelligence-based, algorithmic engine. It partners with websites, devices, and mobile apps, collectively referred to as digital properties, to recommend editorial content and advertisements on the Open Web. Geographically it serves Israel, the United Kingdom, United States, Germany, Rest of the world. It generates the majority of its revenue from the United States.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.